Back

Which factors influence decisions to withdraw from eculizumab: a qualitative study of patients diagnosed with aHUS

2025-07-21 nephrology Title + abstract only
View on medRxiv
Show abstract

BackgroundAtypical haemolytic uremic syndrome (aHUS) is a rare life-threatening disease. Lifelong treatment with intravenous eculizumab every two/three weeks was recommended but evidence is emerging that patients can stop eculizumab and restart should they relapse. However, little is known about the opinions and needs of aHUS patients on withdrawal. ObjectiveWe aimed to understand the factors that impact on decisions to withdraw from treatment. MethodsWe analysed in-depth telephone interviews ...

Predicted journal destinations